WuXi Biologics Receives The Asset ESG Corporate Platinum Award for Second Consecutive Year
Shanghai, China, Feb. 10, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it received the “Platinum Award” in The Asset ESG Corporate Awards 2022. This marks the second consecutive year the company has received the award.
As a widely recognized business news and research organization, The Asset evaluates companies regarding their Environmental, Social, and Governance (ESG) responsibility and sustainability. For its annual ESG Corporate Awards, the organization reviews a wide range of metrics, including energy consumption and GHG emissions, waste and water management, supplier codes of conduct, sustainability financing, and corporate governance.
Dr. Chris Chen, WuXi Biologics’ CEO and Chairperson of the company’s ESG Committee, commented, “We are very pleased to once again receive The Asset’s Platinum Award, which demonstrates our role as an industry ESG leader. During the past year, WuXi Biologics’ ESG commitments and proactive efforts were widely recognized, earning excellent marks from multiple rating agencies and index providers. We appreciate the trust that global partners, investors and local communities have in us. We will continue to make ESG a core competency and to implement related strategies – the better to enable our global partners for the benefit of patients worldwide.”
WuXi Biologics views ESG responsibilities as an integral component of its business strategy and works to meet firm targets and achieve sustainable performance. In 2022, the company established cross-functional task forces to work on core ESG topics: Climate Change; Site Sustainability; Diversity, Equity, and Inclusion (DEI); Responsible governance; and Sustainable Procurement. It has made continual progress in these areas. Additionally, WuXi Biologics shoulders social responsibilities with dedicated resources and contributions. In 2022, the company continued its tradition of helping patients with rare diseases, and also made donations to support earthquake rescue in Sichuan.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com